A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

(2022) Emma C. Hulshof et al.   EUROPEAN JOURNAL OF CANCER

UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review

(2022) Yaoyuan Li et al.   Frontiers in Oncology

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series

(2022) Hsiang-Lin Tsai et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Relative Dose Intensity of Chemotherapy and Survival in Advanced Stage Solid Tumor Cancer Patients: A Systematic Review and Meta‐Analysis

(2021) Carrie M Nielson et al.   ONCOLOGIST

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang

(2020) Shaojun Chen et al.   BMC GASTROENTEROLOGY

Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST)

(2020) Hsiang-Lin Tsai et al.   EUROPEAN JOURNAL OF CANCER

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

(2018) David Páez et al.   BRITISH JOURNAL OF CANCER

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians

(2013) X Liu et al.   PHARMACOGENOMICS JOURNAL

Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk

(2010) Z.-Y. Hu et al.   CLINICAL CANCER RESEARCH

Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

(2009) Giuseppe Toffoli et al.   JOURNAL OF CLINICAL ONCOLOGY

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER

High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?

(2008) Michel Ducreux et al.   ONCOLOGY